作者
Sapna Saini,Neeraja Suresh,Shailendra Dwivedi,Akash Bansal,Shashank Shekhar,Ruchika Agrawal,Sudhir Shyam Kushwaha,Praveen Sharma,Vibha Dutta
摘要
Chimeric antigen receptor (CAR) T-cell therapy is one of the most significant immunotherapeutic strategies for hematological malignancies, achieving durable remission in otherwise refractory cases. This review highlights the fundamental design principles, molecular mechanisms, clinical applications, and global regulatory perspectives of CAR T-cell therapy. The therapy involves ex vivo genetic modification of autologous T-cells to express synthetic receptors that integrate antigen-recognition and intracellular signaling domains, thereby enabling specific and potent cytotoxicity independent of major histocompatibility complex restriction. Successive generations of CAR constructs have incorporated co-stimulatory motifs (CD28, 4-1BB, and OX40), cytokine secretion modules, and signaling adaptors Interleukin-2 (IL-2) receptor beta chain, signal transducer, and activator of transcription 3 to enhance proliferation, persistence, and anti-cancer activity. Mechanistically, CAR T-cells mediate tumor destruction through perforin granzyme-dependent cytolysis, Fas ligand/tumor necrosis factor-alpha-induced apoptosis, and cytokine release, primarily IL-2 and interferon-gamma. The U. S. Food and Drug Administration has approved six CAR T-cell products, namely Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti, mainly targeting CD19 or B-cell maturation antigen antigens. Despite remarkable efficacy in B-cell malignancies, therapeutic challenges remain, including antigen escape, immune-suppressive tumor microenvironment, cytokine release syndrome, neurotoxicity, and high manufacturing cost. Current innovations such as armored CARs, universal allogeneic CARs, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-mediated editing, and artificial intelligence-driven optimization aim to overcome these limitations and expand applications toward solid tumors and autoimmune disorders. A comparative overview of global regulatory frameworks highlights the differences in clinical accessibility and cost-effectiveness across the regions. Collectively, this review provides a comprehensive synthesis of mechanistic insights, technological progress, and translational opportunities in the evolving landscape of CAR T-cell therapy.